Single-cell sequencing also showed that the percentage of T-cell subgroups changed after treatment with ibrutinib, particularly the percentage of CD8+T cells, which increased gradually until 4 months, while CD4+T cells decreased gradually, which coincided with the progressive reduction of CLL cells (20). Here, CD8A is linked to B-cell chronic lymphocytic leukemia.